217 related articles for article (PubMed ID: 23870704)
1. Fast selection of maribavir resistant cytomegalovirus in a bone marrow transplant recipient.
Schubert A; Ehlert K; Schuler-Luettmann S; Gentner E; Mertens T; Michel D
BMC Infect Dis; 2013 Jul; 13():330. PubMed ID: 23870704
[TBL] [Abstract][Full Text] [Related]
2. Accelerated evolution of maribavir resistance in a cytomegalovirus exonuclease domain II mutant.
Chou S; Marousek GI
J Virol; 2008 Jan; 82(1):246-53. PubMed ID: 17942550
[TBL] [Abstract][Full Text] [Related]
3. Clinical development of letermovir and maribavir: Overview of human cytomegalovirus drug resistance.
Piret J; Boivin G
Antiviral Res; 2019 Mar; 163():91-105. PubMed ID: 30690043
[TBL] [Abstract][Full Text] [Related]
4. Virologic characterization of multidrug-resistant cytomegalovirus infection in 2 transplant recipients treated with maribavir.
Strasfeld L; Lee I; Tatarowicz W; Villano S; Chou S
J Infect Dis; 2010 Jul; 202(1):104-8. PubMed ID: 20504236
[TBL] [Abstract][Full Text] [Related]
5. Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients.
Chou S; Alain S; Cervera C; Chemaly RF; Kotton CN; Lundgren J; Papanicolaou GA; Pereira MR; Wu JJ; Murray RA; Buss NE; Fournier M
J Infect Dis; 2024 Feb; 229(2):413-421. PubMed ID: 37506264
[TBL] [Abstract][Full Text] [Related]
6. Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients.
Avery RK; Marty FM; Strasfeld L; Lee I; Arrieta A; Chou S; Tatarowicz W; Villano S
Transpl Infect Dis; 2010 Dec; 12(6):489-96. PubMed ID: 20682012
[TBL] [Abstract][Full Text] [Related]
7. Phenotype and Genotype Study of Novel C480F Maribavir-Ganciclovir Cross-Resistance Mutation Detected in Hematopoietic Stem Cell and Solid Organ Transplant Recipients.
Santos Bravo M; Plault N; Sánchez Palomino S; Mosquera Gutierrez MM; Fernández Avilés F; Suarez Lledo M; Sabé Fernández N; Rovira M; Alain S; Marcos Maeso MÁ
J Infect Dis; 2021 Sep; 224(6):1024-1028. PubMed ID: 33475730
[TBL] [Abstract][Full Text] [Related]
8. Effects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivo.
Chou S; Hakki M; Villano S
Antiviral Res; 2012 Aug; 95(2):88-92. PubMed ID: 22664236
[TBL] [Abstract][Full Text] [Related]
9. Maribavir antagonizes the antiviral action of ganciclovir on human cytomegalovirus.
Chou S; Marousek GI
Antimicrob Agents Chemother; 2006 Oct; 50(10):3470-2. PubMed ID: 17005835
[TBL] [Abstract][Full Text] [Related]
10. Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection.
Chou S; Wu J; Song K; Bo T
Antiviral Res; 2019 Dec; 172():104616. PubMed ID: 31568799
[TBL] [Abstract][Full Text] [Related]
11. Maribavir for Refractory or Resistant Cytomegalovirus Infections in Hematopoietic-cell or Solid-organ Transplant Recipients: A Randomized, Dose-ranging, Double-blind, Phase 2 Study.
Papanicolaou GA; Silveira FP; Langston AA; Pereira MR; Avery RK; Uknis M; Wijatyk A; Wu J; Boeckh M; Marty FM; Villano S
Clin Infect Dis; 2019 Apr; 68(8):1255-1264. PubMed ID: 30329038
[TBL] [Abstract][Full Text] [Related]
12. Maribavir for Preemptive Treatment of Cytomegalovirus Reactivation.
Maertens J; Cordonnier C; Jaksch P; Poiré X; Uknis M; Wu J; Wijatyk A; Saliba F; Witzke O; Villano S
N Engl J Med; 2019 Sep; 381(12):1136-1147. PubMed ID: 31532960
[TBL] [Abstract][Full Text] [Related]
13. Cytomegalovirus UL97 kinase mutations that confer maribavir resistance.
Chou S; Wechel LC; Marousek GI
J Infect Dis; 2007 Jul; 196(1):91-4. PubMed ID: 17538888
[TBL] [Abstract][Full Text] [Related]
14. Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet.
Drew WL; Miner RC; Marousek GI; Chou S
J Clin Virol; 2006 Oct; 37(2):124-7. PubMed ID: 16962820
[TBL] [Abstract][Full Text] [Related]
15. Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing.
Chou S; Watters M; Sinha R; Kleiboeker S
Antiviral Res; 2021 Sep; 193():105139. PubMed ID: 34273445
[TBL] [Abstract][Full Text] [Related]
16. Maribavir use in practice for cytomegalovirus infection in French transplantation centers.
Alain S; Revest M; Veyer D; Essig M; Rerolles JP; Rawlinson W; Mengelle C; Huynh A; Kamar N; Garrigue I; Kaminski H; Segard C; Presne C; Mazeron MC; Avettant-Fenoël V; Lecuit M; Lortholary O; Coaquette A; Hantz S; Leruez-Ville M; Ploy MC
Transplant Proc; 2013 May; 45(4):1603-7. PubMed ID: 23726629
[TBL] [Abstract][Full Text] [Related]
17. Maribavir: First Approval.
Kang C
Drugs; 2022 Feb; 82(3):335-340. PubMed ID: 35147913
[TBL] [Abstract][Full Text] [Related]
18. Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir.
Chou S
Rev Med Virol; 2008; 18(4):233-46. PubMed ID: 18383425
[TBL] [Abstract][Full Text] [Related]
19. Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir.
Chou S
Antimicrob Agents Chemother; 2009 Jan; 53(1):81-5. PubMed ID: 18981262
[TBL] [Abstract][Full Text] [Related]
20. Successful oral treatment of Ganciclovir resistant cytomegalovirus with Maribavir in the context of primary immunodeficiency: First case report and review.
Bright PD; Gompels M; Donati M; Johnston S
J Clin Virol; 2017 Feb; 87():12-16. PubMed ID: 27987421
[No Abstract] [Full Text] [Related]
[Next] [New Search]
